Preparing healthcare companies for success
in the value-based economy

Real Endpoints helps our clients gain competitive advantage in market access
based on three primary assets:

  • Insights from our close working relationships with biopharma and payers
  • Objective, data-driven proprietary tools that reflect market reality for
    biopharma therapies and diagnostics
  • Creative, deeply experienced, solution-oriented people

Client Login >


Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >


Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

News and Events

REPC Webinar: War Stories (the scars) of Budget Impact Modeling

Speaker: Dan Danielson, Pharmacy Manager, Premera BlueCross
Speaker: Dan Olendorf, Chief Scientific Officer, Institute for Clinical & Economic Review (ICER)
Moderator: Jane Barlow, EVP & Chief Clinical Officer, Real Endpoints

Adventures in over-, under-, and correctly estimating drug costs…and defining what’s worth the extra money.

January 17, 2018
3pm EST


request presentation >

Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

by Emily Hayes

Labeling for reduction of cardiovascular risk may help a bit with payers, but the "twin problem" of pricing and lack of patient adherence is likely to continue to present hurdles for reimbursement.

December 1, 2017


news >

Proving the Value of Value-Based Deals

by Ed Silverman

As controversy continues over pharmaceutical pricing, more drugmakers are eyeing deals that peg health plan cost to outcomes to boost volume and win formulary placement. But these deals are challenging to construct and to date there is little evidence that they reduce costs for patients.

November 20, 2017

In Vivo

news >

10th Hub & SPP Model Optimization Conference

Attendee: Real Endpoints Team

Over 700 leaders in Patient Access, Brand Management, Reimbursement and Specialty Distribution across the industry have benefited from CBI’s Hub and SPP Model Optimization conference series.

February 27, 2018 -
February 28, 2018

Philadelphia, PA

event >

Recent Insights

view archive >

February 20, 2018

Harvard Pilgrim and Illumina sign first-of-its-kind value-based contract

Real Endpoints plays a valuable role in orchestrating a first-of-its-kind value-based contract between Harvard Pilgrim and Illumina by introducing the parties and helping to craft the deal structure. Real Endpoints will provide all analytics and financial reconciliation for the initiative.

read full press release >

January 11, 2018

Drug Pricing Pro Roger Longman of Real Endpoints Says Spark Therapeutics Is Making the Right Moves

Roger Longman, CEO of Real Endpoints, a firm assisting pharma companies with their pricing strategies, discusses the state of the value-based pricing market while lending some insights on what specialty drug companies like Spark can do to get payers on board with higher prices.

Listen to full insight podcast >